HORIBA UK Ltd, Medical announces a significant development of its in vitro diagnostics product offering with the launch of its new Yumizen G range of instruments and reagents. Marking a milestone in its new product development programme, the Yumizen G range extends HORIBA Medical’s Haematology portfolio into the complementary field of Haemostasis, a new discipline for the company.
For over 30 years, HORIBA Medical has developed a reputation for expertise and excellence in blood cell analysis. This scientific knowledge, innovation, leadership and cutting-edge technology has now been utilised to deliver the new and comprehensive range of Yumizen G systems and reagents for coagulation diagnostics.
HORIBA Medical’s new Yumizen G systems are user friendly, efficient and secure. In combination with specifically developed and optimized ready-to-use reagents, Yumizen G provides a high quality and cost-effective range of haemostasis solutions that will fit any laboratory size or requirement. The range includes:
Commenting on the launch of this comprehensive new coagulation analysis offering, Cleve Wright, Director, HORIBA Medical UK said, “By leveraging our extensive expertise in the Haematology field, we have significantly broadened our scope in blood disease analysis into a complementary discipline. This means that HORIBA Medical is now able to offer customers a dedicated and specific blood analysis solution to suit any laboratory. We will be further building on our new Haemostasis product range in the very near future.”